Becton, Dickinson and Company

NYSE:BDX

Medical - Instruments & Supplies

Healthcare
$216.08 +1.67%

+$2.36 today

Market cap
$58.86B
Beta
0.28
P/E (TTM)
35.5
EPS (TTM)
$4.06
Dividend yield
2.60%
52W Low $127.59High $187.35

Volume 1.32M

Average 2.76M

BDX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Becton, Dickinson and CompanyNYSE: BDX

Operating Income · Q4 FY2026 · quarter ended Sep 2026

Operating income growth accelerates

Q4 FY2026 operating income of $1.03B rose 48.1% year over year, ahead of the -7.6% change in trailing-twelve-month operating income. Sequentially, it rose 55.7% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.

Context

  • Operating income amounted to 11.6% of revenue in FY2026, down 0.2 pp from a year earlier.
  • Operating income increased in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 10 analysts of $4.98B (+120.7%) for the fiscal year ending Sep 2027, a step up from the -12.5% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.03B+55.7% QoQ
Last fiscal yearSep 2026
$2.26B-12.5% YoY
LTMSep 2026
$2.38B-7.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.1%+50.1%+2.0 pp
1 year-12.5%+120.7%+133.2 pp
3-year CAGR+2.2%+35.6%+33.3 pp
5-year CAGR+22.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2026
2.26B USD
Year-over-year change
-12.5%
4-year CAGR
-0.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How BDX compares with its peers on the latest reported figures

  • BDX's LTM Sep 2026 operating income of $2.38B is the 3rd highest of the 11 companies compared; the peer median is $263.93M.
  • Its year-over-year change of -7.6% is the 8th highest of 11, against a peer median of +10.3%.
  • Operating income amounts to 11.8% of revenue for BDX, versus a peer median of 14.4%.
BDX Competitors Peer median
Operating Income for BDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$7.35B -5.6%-1.3%15.2%
MDTMedtronic plcLTM Jul 2026$6.79B +10.8%+5.6%18.1%
BDXBecton, Dickinson and CompanyLTM Sep 2026$2.38B -7.6%+2.2%11.8%
SOLVSolventum CorporationLTM Jun 2026$2.08B +167.3%+8.8%25.0%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$686.5M +9.8%-6.8%20.6%
EMBCEmbecta Corp.LTM Mar 2026$310.5M +26.8%-4.5%29.8%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$217.37M +22.9%+28.2%13.5%
ICUIICU Medical, Inc.LTM Jun 2026$108.76M +56.7%—5.0%
TFXTeleflex IncorporatedLTM Jun 2026$87.08M -72.8%-20.0%3.3%
BLFSBioLife Solutions, Inc.LTM Mar 2026-$10.89M -115.5%—10.9%
BAXBaxter International Inc.LTM Jun 2026-$274M -783.9%—2.4%
Peer median (excluding BDX) $263.93M+10.3%-1.3%14.4%

Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue18.87B19.37B20.18B21.84B19.46B
Cost of Revenue10.39B11.2B11.05B11.92B10.24B
Gross Profit8.48B8.17B9.13B9.92B9.21B
Gross Margin44.9%42.2%45.2%45.4%47.4%
Research & Development1.26B1.24B1.19B1.26B988M
Selling, General & Admin4.71B4.72B4.86B5.28B4.97B
Operating Expenses6.2B6.06B6.73B7.35B6.96B
Depreciation & Amortization2.23B2.29B2.29B2.46B2.24B
EBITDA4.41B4.4B4.82B4.96B4.61B
EBITDA Margin23.4%22.7%23.9%22.7%23.7%
Operating Income2.28B2.11B2.4B2.58B2.26B
Operating Margin12.1%10.9%11.9%11.8%11.6%
Interest Income16M49M163M38M27M
Interest Expense398M452M528M613M564M
Other Income / Expenses(499M)(449M)(392M)(696M)(451M)
Income Before Tax1.78B1.66B2.01B1.88B1.81B
Pre-Tax Margin9.4%8.6%9.9%8.6%9.3%
Income Tax Expense148M132M300M204M388M
Net Income1.78B1.48B1.71B1.68B1.15B
Net Margin9.4%7.7%8.4%7.7%5.9%
EPS (Basic)5.934.975.885.844.11
EPS (Diluted)5.884.945.865.834.09
Weighted Avg Shares285.01M286.28M289.76M286.61M278.49M
Weighted Avg Shares (Diluted)287.36M288.39M291.01M287.12M279.94M

Becton, Dickinson and Company

NYSE:BDX

Intrinsic Alpha fair value

Locked

Current Price

$216.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.